ISSN: 2167-7689
Pharmaceutical Regulatory Affairs: Open Access
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business
 

BSE-Prion

Hideharu Shintani*
Faculty of Science and Engineering, Chuo University, 1-13-27, Kasuga, Bunkyo, 112-8551, Tokyo, Japan
Corresponding Author : Hideharu Shintani
Faculty of Science and Engineering, Chuo University
1-13-27, Kasuga, Bunkyo, 112-8551, Tokyo, Japan
Tel: +81425922336
Fax: +81425922336
E-mail: shintani@mail.hinocatv.ne.jp
Received May 16, 2014; Accepted May 19, 2014; Published June 05, 2014
Citation: Shintani H (2014) BSE-Prion. Pharmaceut Reg Affairs 3:e133. doi: 10.4172/2167-7689.1000e133
Copyright: © 2014 Shintani H. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Pharmaceutical Regulatory Affairs: Open Access

Adventitious agents are those that are not inherent in the production of biopharmaceuticals. Microbial adventitious agents include viruses, bacteria, fungi, and mycoplasma. Transmissible spongiform encephalopathy (TSE) agents are also potential adventitious agents. Raw materials may contain adventitious agents. Adventitious agents can be introduced during establishment of cell lines, cell culture/ fermentation, capture and downstream processing steps, formulation/ filling, and even during drug delivery Therapeutic biotechnology products have an excellent safety record. However, the potential introduction of adventitious agents must continually be evaluated. The testing that is performed for this purpose is addressed in regulatory documents that include ICH guidelines, US. Points to Consider, and European, U.S., and Japanese Pharmacopoeia (EP,USP and JP) documents. In some cases, 9 CFR (U.S.Code of Federal Regulations) and 21 CFR, 211 and 610 are applicable.
Since biopharmaceuticals encompass many types of products, there is considerable variability in risks from adventitious agents. In all cases, however, the use of Good Manufacturing Practices (GMPs) (e.g., environmental controls, control of raw materials and personnel flow, and cleaning), suitable safety testing programs, and process validation (including viral and sometimes mycoplasma clearance evaluation) helps to ensure patient confidence in biopharmaceuticals. Some products have minimal inherent risk associated with the introduction of adventitious agents (e.g., recombinant products produced in bacteria). Other types of products, such as those used for cell or gene therapy, are often at the other end of the spectrum and may be associated with greater risk due to their inability to tolerate rigorous processing conditions. Greater potential risks are often associated with the use of human cells and anima1-derived raw materials. Of particular concern are materials derived from bovine and porcine sources. When viable cells are a component of the product (as in ex vivo transduction), there may not be sufficient time to perform the required safety testing. In such cases, product may be released prior to completion of relevant tests for adventitious agents, although this testing is still mandated in order to demonstrate that the processes are being performed under adequate controls to maintain patient safety. A risk/benefit analysis determines whether the use of these products is warranted. We need to prevent and control of risks arising from various stages of production. We must confirm that several risks are associated with various sources and must not overlook the risks associated with several sources.
Select your language of interest to view the total content in your interested language
 
Share This Article
   
 
   
 
Relevant Topics
Disc
Disc Advances in Bioavailability
Disc Advances in pharmaceutical analytical methods
Disc Adverse Effects
Disc Air analysis
Disc Anvisa Bioequivalence
Disc Anvisa regulatory guidelines
Disc BA/BE Studies
Disc Bioequivalence Anticancers
Disc Bioequivalence Antidiabetics
Disc Bioequivalence Antidiuretics
Disc Bioequivalence Antipsychotics
Disc Bioequivalence Cardiovascular Products
Disc Bioequivalence Study Design
Disc Bioequivalence Study Protocols
Disc Biopharmaceutics
Disc Biosimilars
Disc British regulatory guidelines
Disc Causality Assesment
Disc Chemical analysis
Disc Clinical Cancer Trials
Disc Clinical Drug Trial
Disc Clinical Pharmacovigilance
Disc Clinical Trials Pharmacovigilance
Disc Competitive analysis of drugs
Disc Drug Monitoring
Disc Drug Safety Survillance
Disc Drug analysis
Disc Drug devices
Disc Europe Pharmacovigilance
Disc European Bioequivalence
Disc Europian regulatory guidelines
Disc Experimental Drug Trial
Disc FDA Bioequivalence
Disc Good Pharmacovigilance Practice
Disc In vitro Bioequivalence
Disc Japan Pharmacovigilance
Disc Japan regulatory guidelines
Disc Medical Literature
Disc Medical devices regulations
Disc Medication Error
Disc Paid Clinical Trials
Disc Periodic Safety Update Reports
Disc Pharma Risk Management
Disc Pharmaceutical analysis
Disc Pharmaceutical analytical market
Disc Pharmaceutical care
Disc Pharmaceutical companies and regulatory guidelines
Disc Pharmaceutical ethics
Disc Pharmaceutical formulation
Disc Pharmaceutical technology
Disc Pharmaceutics
Disc Pharmacovigilance Regulatory Updates
Disc Pharmacovigilance and Risk Management
Disc Pharmacovigilance for Alternative Medicine
Disc Product analysis and marketing
Disc Quality assurance in pharmaceutical analysis
Disc Quality assurance in regulatory affairs
Disc Regulatory Requirements in Bioequivalence
Disc Regulatory affairs
Disc Regulatory affairs for clinical trails
Disc Regulatory compliance
Disc Regulatory consulting and market analysis
Disc Regulatory requirements of pharmaceutical products
Disc Regulatory services and market analysis
Disc Spectrometry
Disc UK Pharmacovigilance
Disc US FDA guidelines
Disc US Pharmacovigilance
Disc Validation
Disc Veterinary Pharmacovigilance
 
Recommended Journals
Disc Pharmacovigilance Journal
Disc Pharmaceutical Analysis Journal
Disc Bioequivalence Journal
  View More»
 
Recommended Conferences
Disc 6th Pharmaceutical Regulatory Affairs
September 15-16, 2016, San Antonio, USA
Disc 7th Analytical Techniques Conference
September 29-Oct 1, 2016, Miami, USA
Disc Pharmaceutical Methods Development Conference
October 20-22, 2016, Dubai, UAE
 
Article Tools
Disc Export citation
Disc Share/Blog this article
 
Article usage
  Total views: 11149
  [From(publication date):
October-2014 - Jun 28, 2016]
  Breakdown by view type
  HTML page views : 7422
  PDF downloads :3727
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

 
OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsinc.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsinc.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsinc.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsinc.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsinc.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsinc.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsinc.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsinc.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsinc.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsinc.com

1-702-714-7001Extn: 9039

Materials Science Journals

Rachle Green

materialsci@omicsinc.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsinc.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsinc.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsinc.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsinc.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsinc.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version